{"id":"W2336457573","doi":"10.1200/jco.2015.33.3_suppl.9","title":"INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG), first results.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; Saint John Regional Hospital; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Regorafenib; Population; Placebo; Ramucirumab; Adverse effect; Phases of clinical research; Gastroenterology; Cancer; Progression-free survival; Refractory (planetary science); Surgery; Oncology; Chemotherapy; Clinical trial; Colorectal cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001572479,0.002246684,0.003354617,0.000641813,0.000503612,0.001134275,0.0010935,0.001649811,0.0131283],"category_scores_gemma":[0.001704305,0.000821015,0.001807431,0.0005920996,0.001201257,0.001178733,0.0005269696,0.00300825,0.001967783],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006551869,"about_ca_system_score_gemma":0.001348196,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006150022,"about_ca_topic_score_gemma":0.002026839,"domain_scores_codex":[0.9995092,0.0002469763,0.00003365639,0.0000805082,0.00005484546,0.00007488747],"domain_scores_gemma":[0.9994305,0.0001018872,0.0001711111,0.00005689978,0.00004471511,0.0001949358],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9773307,0.006267837,0.0005346445,0.0007430516,0.0007569804,0.00003405889,0.00004244814,0.0001580086,0.002158021,0.00009094982,0.001019813,0.01086341],"study_design_scores_gemma":[0.9710537,0.02729063,0.0006108294,0.00001616682,0.0002276237,0.00001631295,0.000009364639,0.00007596379,0.0001450496,0.00004660304,0.0005028325,0.000004992407],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9574454,0.01024464,0.001281285,0.001449491,0.001029939,0.01772849,0.004413771,0.000506517,0.005900351],"genre_scores_gemma":[0.9543685,0.006139083,0.002615977,0.002354156,0.0009896173,0.0216639,0.003899222,0.00007134302,0.007898233],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0131283,"threshold_uncertainty_score":0.04391855,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2245218974730568,"score_gpt":0.5075961454477481,"score_spread":0.2830742479746913,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}